Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Beats Q3 Earnings Estimates

LAVAL, Quebec, Nov. 2, 2021 /PRNewswire/ -- Third-Quarter 2021 Financial Results Revenues of $2.111 Billion GAAP Net Income of $188 Million Adjusted EBITDA (non-GAAP)1 of $885 Million GAAP Cash Generated from Operations of $564 Million Expects to Launch Solta Medical IPO 2 in December 2021 or January 2022 and Bausch + Lomb IPO Approximately 30 Days Following Solta Medical IPO 3 Reaffirmed 2021 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its third-quarter 2021 financial results. "Our third-quarter 2021 results continue to demonstrate that our recovery from the effects of the COVID-19 pandemic remains in progress across our business segments," said Joseph C.

Bausch Health Companies Inc. Announces Third-Quarter 2021 Results

Shares of Bausch Health Cos. Inc. BHC, +1.60% gained 1.2% in premarket trading on Tuesday after the company said it plans to spin off its medical aesthetics business in the next three months.

Bausch says it plans to spin off Solta Medical aesthetics business

Company to Also Host Promotional Education Events at Both Meetings LAVAL, QB, Nov. 1, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that seven scientific posters involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meetings of the American Academy of Optometry in Boston (Nov. 3-6, 2021) and American Academy of Ophthalmology in New Orleans (Nov. 12-15, 2021). The company will also host several promotional education events.

Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings

Salix Pharmaceuticals' First Liver Health Annual Trends Report   Highlights Urgent Need for Evidence-Based Guidelines to be Adopted by Physicians LAVAL, Quebec, Oct. 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal and liver diseases, today released key findings from a survey of health care providers (HCP) treating chronic liver disease (CLD), including potential gaps in prevention and diagnosis efforts. The Liver Health Annual Trends Report, which surveyed 100 physicians active in the management and treatment of CLD, offers facts and trends about CLD in America, a disease that affects an estimated 4.5 million adults in the United States.1 Research indicates that more people aged 25-54 die from CLD and cirrhosis than diabetes or stroke.2 The results of this survey and in-depth interviews of physicians suggest CLD has not received the attention or level of effort needed for adequate prevention, diagnosis, and standardization of its management.

New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States

Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented LAVAL, Quebec, Oct. 25, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the treatment of gastrointestinal (GI) diseases and conditions, today announced seven posters featuring new data for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) are being presented at the American College of Gastroenterology® (ACG) 2021 Annual Scientific Meeting, which is taking place Oct. 22-27, 2021 in Las Vegas. "Salix is pleased to present important new clinical data on three key products in our gastrointestinal portfolio at ACG's annual scientific meeting," said Robert Spurr, president, Salix Pharmaceuticals.

Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting

Clearside Biomedical

XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid LAVAL, QC and ALPHARETTA, Ga., Oct. 25, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced that the U.S. Food and Drug Administration (FDA) has approved XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation1.

Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

LAVAL, QC, Oct. 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Tom Vadaketh will join the Company as Chief Financial Officer (CFO) for its Bausch Pharma* business effective Jan. 3, 2022. Sam Eldessouky, current CFO of the Company, will become CFO of Bausch + Lomb contingent and effective upon the closing of the initial public offering (IPO) of Bausch + Lomb, and at that time, Mr.

Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer

Eight Poster Presentations Include New Analyses of ARAZLO®,   DUOBRII® and SILIQ® LAVAL, QC, Oct. 19, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of eight posters during the Fall Clinical Dermatology Conference, which takes place Oct. 21-24, 2021. The presentations will feature new efficacy and safety analyses of ARAZLO® (tazarotene) Lotion, 0.045%, long-term outcomes of DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, quality of life improvement with SILIQ® (brodalumab) injection 210 mg/1.5 ml and new onychomycosis treatment recommendations.

Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference

MONTPELLIER, France--(BUSINESS WIRE)--Bausch + Lomb today announced positive outcomes following the one-year real-world evaluation of its premium LuxSmart™ lens, since its European launch.

Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience

LAVAL, QC, Oct. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m.

Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

LAVAL, QC and HEIDELBERG, Germany, Sept. 30, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH ("Novaliq"), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

LAVAL, QC, Sept. 29, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Environmental, Social and Governance (ESG) Report (previously referred to as the "Corporate Social Responsibility" or "CSR" Report), highlighting the Company's ongoing commitment to drive a sustainable and equitable impact for its various stakeholders.

Bausch Health Releases Annual Environmental, Social and Governance Report

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?

One analyst crunches the numbers to come up with a share price valuation well above current levels.

Why Bausch Health Companies Stock Zoomed 8% Higher Today

Biogen

BioNTech SE

CRISPR Therapeutics

Moderna

Pfizer

Teva Pharmaceutical

Vertex Pharmaceuticals

Viatris

SPDR S&P Pharmaceuticals ETF

With drug pricing reform on the horizon, investors may want to analyze their allocation.

Is Now the Time to Ditch Pharma Stocks?

Morgan Stanley

Bausch Health Companies, Inc. (BHC) CEO Joseph Papa on Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

Bausch Health Cos. Inc. BHC, -0.59% said Monday it has filed confidentially for the initial public offerings of its eye health business Bausch & Lomb, and its medical aesthetics business Global Solta.

Bausch Health files confidentially for IPOs of eye care business and medical aesthetics business

Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first approved Glumetza, a once-daily extended-release version of metformin, owned by Depomed, now known as Assertio Holdings Inc (NASDAQ: ASRT), and Santarus, which Bausch later acquired.

Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?

Data to Feature New Health Economic Outcomes Research of Treatment of Emergency Department Patients with Opioid-Induced Constipation LAVAL, QC, Sept. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that new Health Economic Outcomes Research (HEOR) data featuring RELISTOR® (methylnaltrexone bromide) will be shared at PAINWeek 2021 taking place in Las Vegas from Sept.

Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

Activists are circling the company and pressuring to unlock shareholder value. Stock still looks attractive from a valuation and near-term catalyst standpoint.

Activist Spotlight: Activists In Bausch Health With Catalysts On Horizon

Amphastar Pharma

Dr. Reddy's Labs

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

News for Bausch Health Companies Inc Stock (BHC)